Get the Stockscreener App
24.65
1.48%
0.36
Pre-market:
24.65
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $24.65, with a volume of 132.63M.
It is up +1.48% in the last 24 hours and down -3.26% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.29
Open:
$24.28
24h Volume:
132.63M
Relative Volume:
2.53
Market Cap:
$140.15B
Revenue:
$63.83B
Net Income/Loss:
$10.77B
P/E Ratio:
13.11
EPS:
1.8799
Net Cash Flow:
$12.44B
1W Performance:
-0.44%
1M Performance:
-3.26%
6M Performance:
+0.98%
1Y Performance:
-12.90%
1-Day Range:
$24.16
$24.73
1-Week Range:
$24.15
$24.80
52-Week Range:
$20.91
$28.54
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.65 | 138.10B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
862.86 | 757.06B | 59.42B | 18.41B | -50.20M | 20.22 |
|
JNJ
Johnson Johnson
|
188.87 | 455.48B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
218.04 | 403.13B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.79 | 235.26B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
85.98 | 215.51B | 63.99B | 19.05B | 14.72B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Torray Investment Partners LLC Raises Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Sues To Block Metsera’s Move Toward Novo Nordisk Deal - Finimize
Metsera, Inc. Responds to Pfizer Litigation - TradingView
Pfizer Inc. $PFE Shares Sold by TIAA Trust National Association - MarketBeat
United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key PlayersNovartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb - Yahoo Finance
1 Incredible Reason to Buy Pfizer Stock (PFE) in November - Yahoo Finance
U.S. Vasopressin Market Poised for Transformation with - openPR.com
Pfizer sues Novo Nordisk and Metsera - MarketScreener
Pfizer (PFE) Sues Over Metsera Acquisition Bid - GuruFocus
Pfizer sues Metsera, Novo Nordisk to block rival bid - Seeking Alpha
Pfizer (PFE) Q3 Earnings: What To Expect - Yahoo Finance
Key facts: Pfizer to report Q3 earnings on Nov 4; faces legal battle over Metsera - TradingView
Palantir, AMD, Pfizer, Robinhood, McDonald’s, and Many More Stocks to Watch This Week - Barron's
Pfizer sues to block Novo Nordisk's Metsera takeover bid - pharmaphorum
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk - MSN
1 Stock to Buy, 1 Stock to Sell This Week: Palantir, Pfizer - Investing.com
1 Stock to Buy, 1 Stock to Sell This Week: Palantir, Pfizer - Investing.com
SS&H Financial Advisors Inc. Buys 15,668 Shares of Pfizer Inc. $PFE - MarketBeat
Versor Investments LP Boosts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Welch & Forbes LLC Decreases Stake in Pfizer Inc. $PFE - MarketBeat
Is It Time to Dump Your Shares of Pfizer? - sharewise.com
Plato Investment Management Ltd Boosts Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal
Pfizer Races to Save Obesity Drugmaker Deal After Novo’s Bid - MSN
Key facts: Pfizer gains antitrust approval for Metsera; faces lawsuits - TradingView
Pfizer sues Metsera, Novo in effort to enforce buyout deal - BioPharma Dive
Pfizer Sues Metsera to Block Novo Nordisk’s $9B “Bribe” Deal - USA Herald
How Pfizer Inc. stock performs in volatility spikes2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Atlas Private Wealth Advisors Sells 16,303 Shares of Pfizer Inc. $PFE - MarketBeat
Declining Stock and Decent Financials: Is The Market Wrong About Pfizer Inc. (NYSE:PFE)? - Yahoo Finance
Lifeworks Advisors LLC Buys 66,511 Shares of Pfizer Inc. $PFE - MarketBeat
Integrity Alliance LLC. Has $1.26 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer sues to block Novo Nordisk’s bid for Metsera in high-stakes pharma clash - TradingView
Pfizer Inc. $PFE Shares Sold by Pinnacle Associates Ltd. - MarketBeat
Pfizer Sues Metsera, Novo Nordisk Over $9B Buyout 'Bribe' - Law360
Pfizer secures early termination, launches lawsuit over Metsera deal - Global Competition Review
Pfizer Inc. - Britannica
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid - Reuters
Pfizer files lawsuit to block Novo Nordisk's bid for Metsera - Axios
Metsera (MTSR) Responds to Pfizer's Legal Action - GuruFocus
Pfizer Sues Seeking to Block Novo Nordisk’s Effort to Undo Weight-Loss Drug DealWSJ - The Wall Street Journal
Pfizer Gets Nod to Proceed With Metsera Deal From US Regulators - Bloomberg
Pfizer sues Metsera and Novo Nordisk over merger agreement breach - Investing.com
Pfizer (NYSE:PFE) Stock Price Up 1.6%Should You Buy? - MarketBeat
Pfizer sues Metsera, Novo Nordisk for merger deal breach - breakingthenews.net
Pfizer (PFE) Granted Early Termination for Metsera Acquisition - GuruFocus
Pfizer sues Metsera and Novo Nordisk over merger agreement breach By Investing.com - Investing.com Nigeria
Pfizer sues Metsera, Novo Nordisk over breach of merger deal - Reuters
Novo Nordisk (NVO) in Pursuit of Metsera Amid Pfizer's Regulator - GuruFocus
Pfizer wins early US antitrust nod for Metsera deal - Yahoo Finance
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid - Financial Times
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):